B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline
CompanyDeals

B&K Corporation Debuts on HKEX in $900M IPO Backed by Burn Drug Pipeline

OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform
CompanyDeals

OBT and GSK Forge Multi-Target Cancer Collaboration Using OGAP Platform

Lilly to Invest Over $6 Billion in Alabama GLP‑1 Manufacturing Hub for Orforglipron
Company

Lilly to Invest Over $6 Billion in Alabama GLP‑1 Manufacturing Hub for Orforglipron

Sino Biopharm’s Culmerciclib Wins NMPA Approval as First CDK2/4/6 Inhibitor for Breast Cancer
CompanyDrug

Sino Biopharm’s Culmerciclib Wins NMPA Approval as First CDK2/4/6 Inhibitor for Breast Cancer

Insilico Licenses AI‑Designed ISM4808 PHD Inhibitor to TaiGen in Two‑Digit Million Dollar Greater China Deal
CompanyDeals

Insilico Licenses AI‑Designed ISM4808 PHD Inhibitor to TaiGen in Two‑Digit Million Dollar Greater China Deal

Lobemilast (Y‑3) NDA Accepted by NMPA as First Multi‑Target Stroke Neuroprotectant
CompanyDrug

Lobemilast (Y‑3) NDA Accepted by NMPA as First Multi‑Target Stroke Neuroprotectant

Bleecker Bio (Formation) Licenses Lynk’s CNS‑Penetrant TYK2 Inhibitor LNK01006 in $605 M Deal
CompanyDeals

Bleecker Bio (Formation) Licenses Lynk’s CNS‑Penetrant TYK2 Inhibitor LNK01006 in $605 M Deal

Shanghai Pharma’s SPH3127 Renin Inhibitor Wins NMPA Approval for Primary Hypertension
CompanyDrug

Shanghai Pharma’s SPH3127 Renin Inhibitor Wins NMPA Approval for Primary Hypertension

Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo‑Free TIL Therapy for Solid Tumors
CompanyDeals

Juncell Therapeutics Files for HKEX IPO, Pioneering Chemo‑Free TIL Therapy for Solid Tumors

Relation Therapeutics and Novartis Forge $1.7 Billion Alliance for AI‑Driven Atopic Disease Targets
CompanyDeals

Relation Therapeutics and Novartis Forge $1.7 Billion Alliance for AI‑Driven Atopic Disease Targets

Sanofi’s Qfitlia Wins China Approval as First Hemophilia siRNA Therapy
CompanyDrug

Sanofi’s Qfitlia Wins China Approval as First Hemophilia siRNA Therapy

Zealand Pharma and OTR Therapeutics Seal $2.5 Billion Metabolic Disease Partnership
CompanyDeals

Zealand Pharma and OTR Therapeutics Seal $2.5 Billion Metabolic Disease Partnership